Epigenetics

Epigenetics is the control of gene expression without altering the DNA sequence, including DNA methylation, genomic imprinting, maternal effects, gene silencing, nucleolus dominant, dormant transposon activation, and RNA editing. In contrast to classical genetics, which focuses on the effects of gene sequences on biological functions, epigenetics focuses on the mechanisms by which these "epigenetic phenomena" are established and maintained.

Cat. No.	Product name
BP14275	Valemetostat
BP14275	Valemetostat is a first-in-class EZH1/2 dual inhibitor.
BP14274	Urolithin B
BP14274	Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα, and suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass.Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects.
BP14273	UPF 1069
BP14273	UPF 1069 is a specific PARP2 inhibitor ( IC50: 0.3 μM). It is ~27-fold selective against PARP1.
BP14272	UNC926
BP14272	UNC-926 inhibits L3MBTL1 (IC50: 3.9 μM). UNC-926 also exhibits a low micromolar affinity for L3MBTL3. UNC-926 inhibits binding of the 3xMBT domain to H4K20me1. It selectively and dose-dependently inhibits the L3MBTL13xMBT-H4K20me1 interaction. UNC-926 has not an effect on the binding of 53BP1 to H4K20me1.
BP14271	UNC926 hydrochloride
BP14271	UNC926 hydrochloride is a methyl-lysine (Kme) reader domain inhibitor.
BP14270	UNC6852
BP14270	UNC6852 contains an EED ligand (IC50 = 247 nM) and a von Hippel-Lindau ligand and is a selective polycomb repressive complex 2 (PRC2) degrader based on PROTAC.
BP14269	UNC 669
BP14269	UNC669 is an effective and specific MBT (malignant brain tumor) inhibitor with IC50 of 4.2/3.1 uM for L3MBTL1/3.
BP14268	UNC3866 TFA(1872382-47-2 free base)
BP14268	UNC3866 TFA is a potent antagonist of the CBX7-H3 interaction as determined by AlphaScreen.
BP14267	UNC3866
BP14267	UNC3866 is a potent antagonist of the CBX7-H3 interaction as determined by AlphaScreen.
BP14266	UNC1079
BP14266	UNC1079 is an selective L3MBTL3 domain inhibitor
BP14265	UNC0642
BP14265	UNC0642 is an effective and specific G9a/GLP inhibitor (IC50< 2.5 nM).
BP14264	UNC 0631
BP14264	UNC0631 is a effectvie histone methyltransferase G9a inhibitor (IC50=4 nM).
BP14263	UNC0379
BP14263	UNC0379 is a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
BP14262	UNC0321
BP14262	UNC0321 is an effective inhibitor of histone methyltransferase G9a with a Ki of 63 pM and with IC50s 9 nM and 6 nM in ECSD and CLOT assays. UNC0321 inhibits GLP with IC50s of 15 nM and 23 nM in ECSD and CLOT assays.
BP14261	UNC0224
BP14261	UNC0224 is a selective inhibitor of G9a with a Ki of 2.6 nM and IC50 of 15 nM. UNC0224 also potently inhibits GLP with assay-dependent IC50 values of 20-58 nM.
BP14260	UNC0646
BP14260	UNC 0646 is a potent and selective inhibitor of the homologous protein lysine methyltransferases, G9a and GLP (IC50s: 6 nM/15 nM for G9a/GLP). UNC0646 potently blocks G9a/GLP methyltransferase activity in cells (IC50: 10 nM in MCF7 cells); exhibits low cellular toxicity (EC50: 4.7 μM in MCF7 cells).
BP14259	UMB298
BP14259	UMB298 is a potent and selective CBP/P300 bromodomain inhibitor. UMB298 inhibits BRD4 with IC50 of 5193nM.
BP14258	UF010
BP14258	UF010 is a potent and selective HADC inhibitor with IC50 ~0.06 μM, 0.1 μM, 0.5 μM and 1.5 μM for HDACs 3, 2, 1 and 8, respectively.
BP14257	Tucidinostat
BP14257	Tucidinostat is an effective and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8/11 (IC50: 733/432 nM), and shows no effect on HDAC4/5/6/7/9.
BP14256	Tubacin
BP14256	Tubacin is a highly potent and selective, reversible, cell-permeable HDAC6 inhibitor with an IC50 of 4 nM, approximately 350-fold selectivity over HDAC1.